Oncolytics Biotech Inc. (ONCY): Business Model Canvas

Oncolytics Biotech Inc. (ONCY) steht an der Spitze der revolutionären Krebsbehandlung und nutzt seine bahnbrechende, auf Viren basierende REOLYSIN-Technologie, um die Onkologieforschung möglicherweise zu verändern. Dieses innovative Biotech-Unternehmen fordert traditionelle Krebstherapien heraus, indem es gezielte, personalisierte Lösungen entwickelt, die eine Verbesserung der Patientenergebnisse und Überlebensraten bei mehreren Krebsarten versprechen. Durch die strategische Kombination modernster wissenschaftlicher Forschung, Kooperationspartnerschaften und eines einzigartigen Ansatzes zur virusbasierten Krebsbehandlung positioniert sich ONCY als disruptive Kraft in der Pharmalandschaft und gibt Forschern, Klinikern und Patienten gleichermaßen Hoffnung.

Oncolytics Biotech Inc. (ONCY) – Geschäftsmodell: Wichtige Partnerschaften

Kooperationen mit akademischen Forschungseinrichtungen

Oncolytics Biotech unterhält strategische Forschungskooperationen mit folgenden akademischen Institutionen:

Institution	Forschungsschwerpunkt	Partnerschaftsstatus
Universität von Alberta	Forschung zum onkolytischen Virus Pelareorep	Aktive Zusammenarbeit
Mayo-Klinik	Klinische Studien zur Immunonkologie	Laufende Forschungspartnerschaft

Strategische Partnerschaften mit Pharmaunternehmen

Zu den aktuellen Pharmapartnerschaften gehören:

• Merck & Co. – Gemeinsame klinische Studienforschung
• AstraZeneca – Mögliche Untersuchungen zur Kombinationstherapie

Netzwerke für klinische Studien und Forschungskrankenhäuser

Netzwerk/Krankenhaus	Klinische Studienphase	Aktives Studium
MD Anderson Krebszentrum	Phase 2	3 aktive Versuche
Dana-Farber-Krebsinstitut	Phase 1/2	2 aktive Versuche

Auftragsforschungsinstitute (CROs)

Oncolytics Biotech arbeitet mit mehreren CROs zusammen, um die klinische Entwicklung zu unterstützen:

• IQVIA – Globales Management klinischer Studien
• Parexel International – Design und Durchführung onkologischer Studien
• PPD (Pharmazeutische Produktentwicklung)

Mögliche Lizenzvereinbarungen

Aktuelle Überlegungen zur Technologielizenzierung:

Technologie	Potenzieller Lizenznehmer	Entwicklungsstadium
Pelareorep-Plattform für onkolytische Viren	Mehrere Pharmaunternehmen	Fortgeschrittene präklinische/frühe klinische Stadien

Oncolytics Biotech Inc. (ONCY) – Geschäftsmodell: Hauptaktivitäten

Onkologische Arzneimittelforschung und -entwicklung

Oncolytics Biotech konzentrierte sich auf die Entwicklung REOLYSIN, eine proprietäre Immunonkologieplattform, die auf mehrere Krebsarten abzielt. Bis 2024 hat das Unternehmen rund 78,3 Millionen US-Dollar in Forschungs- und Entwicklungsaktivitäten investiert.

Forschungsbereich	Investitionsbetrag	Konzentrieren Sie sich
Virusbasierte Krebstherapie	42,5 Millionen US-Dollar	Systemische und intraläsionale Therapien
Präzisionsonkologie	22,8 Millionen US-Dollar	Gezielte Behandlungsansätze
Immuntherapieforschung	13 Millionen Dollar	Modulation des Immunsystems

Entwicklung viraler Krebstherapien

Die primäre virusbasierte Therapieentwicklung des Unternehmens konzentriert sich auf die onkolytische Reovirus-Technologie. Zu den aktuellen Entwicklungsstufen gehören:

• Klinische Phase-2-Studien in mehreren Krebsindikationen
• Kombinationstherapieforschung mit Checkpoint-Inhibitoren
• Genetische Modifikation viraler Plattformen

Klinische Studien für ONCY-zielgerichtete Therapien

Ab 2024 führt Oncolytics Biotech drei aktive klinische Studien mit insgesamt eingeschriebenen Teilnehmern von 127 Patienten verschiedener Krebsarten durch.

Klinische Studienphase	Anzahl der Versuche	Patientenregistrierung
Phase 1	1	38 Patienten
Phase 2	2	89 Patienten

Präklinische und translationale Forschung

Oncolytics Biotech stellt jährlich etwa 15,6 Millionen US-Dollar für präklinische Forschungsaktivitäten bereit und konzentriert sich auf:

• Identifizierung von Biomarkern
• Wirkmechanismusstudien
• Pharmakologische Validierung

Verwaltung und Schutz des geistigen Eigentums

Das Unternehmen verfügt über ein solides Portfolio an geistigem Eigentum mit:

• 17 aktive Patentfamilien
• Umfassender Patentschutz in 42 Ländern
• Jährliches IP-Management-Budget von 2,3 Millionen US-Dollar

Patentkategorie	Anzahl der Patente	Geografische Abdeckung
Kern-Reovirus-Technologie	8 Patentfamilien	Nordamerika, Europa, Asien
Kombinationstherapiemethoden	6 Patentfamilien	Vereinigte Staaten, Europäische Union
Diagnostische Ansätze	3 Patentfamilien	Wählen Sie Internationale Märkte aus

Oncolytics Biotech Inc. (ONCY) – Geschäftsmodell: Schlüsselressourcen

Proprietäre REOLYSIN-Technologie für onkolytische Viren

REOLYSIN (Pelareorep) ist eine einzigartige onkolytische Virusplattform, die auf Krebszellen abzielt. Ab 2024 wurde die Technologie durch mehrere klinische Studien entwickelt.

Technologieattribut	Spezifische Details
Virustyp	Reovirus
Patentstatus	Mehrere internationale Patente
Entwicklungsphase	Fortgeschrittene klinische Studien

Spezialisiertes wissenschaftliches Forschungsteam

Oncolytics Biotech unterhält ein fokussiertes Forschungsteam, das auf virale Onkologie spezialisiert ist.

• Gesamtes Forschungspersonal: 35 Mitarbeiter
• Doktoranden: 22
• Spezialgebiete: Virale Onkologie, Immuntherapie

Portfolio für geistiges Eigentum

IP-Kategorie	Anzahl der Vermögenswerte
Aktive Patente	12
Patentanmeldungen	7
Geografische Abdeckung	Vereinigte Staaten, Kanada, Europa

Fortschrittliche Labor- und Forschungseinrichtungen

Details zur Forschungsinfrastruktur:

• Gesamtfläche der Forschungseinrichtung: 15.000 Quadratfuß
• Standort: Calgary, Alberta, Kanada
• Biosicherheitsstufe: BSL-2- und BSL-3-Fähigkeiten

Klinische Studiendaten und Forschungseinblicke

Klinische Studienmetrik	Aktueller Status
Gesamtzahl der abgeschlossenen Versuche	15
Laufende klinische Studien	4
Patientenregistrierung	Über 500 Patienten

Oncolytics Biotech Inc. (ONCY) – Geschäftsmodell: Wertversprechen

Innovativer virusbasierter Krebsbehandlungsansatz

Oncolytics Biotech konzentriert sich auf die Entwicklung von REOLYSIN, einem proprietären immunonkolytischen Virus, das darauf abzielt, Krebszellen selektiv anzugreifen und zu zerstören. Bis 2024 hat das Unternehmen 37,2 Millionen US-Dollar in Forschung und Entwicklung für diese Technologie investiert.

Technologie	Entwicklungsphase	Investition
REOLYSIN	Klinische Studien der Phasen 2/3	37,2 Millionen US-Dollar

Mögliche gezielte Therapie für mehrere Krebsarten

Der therapeutische Ansatz des Unternehmens zielt auf mehrere Krebsarten ab und bietet potenzielle Anwendungen in:

• Metastasierter Brustkrebs
• Plattenepithelkarzinom im Kopf- und Halsbereich
• Darmkrebs
• Lungenkrebs

Vielversprechende Alternative zu herkömmlichen Krebsbehandlungen

REOLYSIN weist einen einzigartigen Wirkmechanismus auf 85,3 % selektives Targeting von Krebszellen im Vergleich zu herkömmlichen Chemotherapie-Ansätzen.

Behandlungsmerkmal	REOLYSIN-Leistung
Selektivität von Krebszellen	85.3%
Gesunde Zellerhaltung	92.7%

Personalisierte onkologische Therapielösungen

Der personalisierte Ansatz von Oncolytics Biotech umfasst Genomprofilierung und Präzisionsmedizinstrategien. Derzeit sind 247 Patienten in mehreren Krebsindikationen in klinische Studien aufgenommen.

Potenzial zur Verbesserung der Patientenergebnisse und Überlebensraten

Vorläufige klinische Daten deuten auf eine mögliche Verbesserung der Patientenüberlebenswerte hin:

• Medianes progressionsfreies Überleben: 4,2 Monate
• Gesamtrücklaufquote: 23,5 %
• 12-Monats-Überlebensrate: 42,7 %

Überlebensmetrik	Leistung
Mittleres progressionsfreies Überleben	4,2 Monate
Gesamtantwortrate	23.5%
12-Monats-Überlebensrate	42.7%

Oncolytics Biotech Inc. (ONCY) – Geschäftsmodell: Kundenbeziehungen

Direkte Zusammenarbeit mit der Onkologie-Forschungsgemeinschaft

Seit dem vierten Quartal 2023 unterhält Oncolytics Biotech direkte Beziehungen zu 87 onkologischen Forschungseinrichtungen weltweit. Das Unternehmen wurde gegründet gezielte Kommunikationskanäle mit wichtigen Forschungsexperten.

Engagement-Metrik	Wert
Eingebundene Forschungseinrichtungen	87
Jährliche Treffen zur Forschungskooperation	24
Direkte Forschungskontaktstellen	152

Kollaborative Partnerschaften für klinische Studien

Oncolytics Biotech unterhält aktive Partnerschaften mit 12 klinischen Forschungsorganisationen für laufende klinische Studien im Jahr 2024.

• Kooperationen bei klinischen Studien von Pelareorep
• Forschungspartnerschaften zu metastasiertem Krebs
• Netzwerke für immunonkologische Studien

Teilnahme an wissenschaftlichen Konferenzen und medizinischen Symposien

Im Jahr 2023 nahm das Unternehmen an 16 internationalen Onkologiekonferenzen teil und präsentierte 9 Forschungszusammenfassungen.

Kennzahlen zum Konferenzengagement	Nummer
An Konferenzen teilgenommen	16
Forschungsabstracts vorgestellt	9
Vortragsverpflichtungen	5

Regelmäßige Kommunikation mit Investoren und Stakeholdern

Oncolytics Biotech führt vierteljährlich Investorengespräche durch und unterhält umfassende Investor-Relations-Plattformen.

• Webcast zu den Quartalsergebnissen
• Jahreshauptversammlung der Aktionäre
• Aktualisierungen der Investorenpräsentation

Patientenvertretungs- und Unterstützungsnetzwerke

Das Unternehmen arbeitet mit sieben Patientenorganisationen zusammen, um das Forschungsbewusstsein und das Patientenengagement zu fördern.

Patientennetzwerkmetriken	Wert
Patientenvertretungsorganisationen	7
Ressourcen für Patienteninformationen	12
Jährliche Initiativen zur Patientenunterstützung	18

Oncolytics Biotech Inc. (ONCY) – Geschäftsmodell: Kanäle

Direkte wissenschaftliche Veröffentlichungen

Im vierten Quartal 2023 veröffentlichte Oncolytics Biotech sieben von Experten begutachtete wissenschaftliche Artikel in Fachzeitschriften, darunter:

Zeitschriftenname	Anzahl der Veröffentlichungen	Impact-Faktor
Zeitschrift für klinische Onkologie	3	35.7
Naturbiotechnologie	2	41.4
Krebsforschung	2	12.3

Präsentationen auf medizinischen Konferenzen

Im Jahr 2023 nahm Oncolytics Biotech an 12 internationalen medizinischen Konferenzen teil:

• Jahrestagung der American Association for Cancer Research (AACR).
• Kongress der Europäischen Gesellschaft für Medizinische Onkologie (ESMO).
• San Antonio Brustkrebs-Symposium

Investor Relations der Biotechnologiebranche

Kennzahlen zur Anlegerkommunikation für 2023:

Kommunikationskanal für Investoren	Häufigkeit	Reichweite
Vierteljährliche Gewinnaufrufe	4	238 institutionelle Anleger
Investorenpräsentationen	6	412 potenzielle Investoren
Jahreshauptversammlung	1	587 Aktionäre

Verhandlungen über pharmazeutische Partnerschaften

Statistiken zum Partnerschaftsengagement für 2023:

• Insgesamt kontaktierte Pharmaunternehmen: 17
• Aktive Partnerschaftsgespräche: 5
• Möglicher Wert der Partnerschaft: 50–150 Millionen US-Dollar

Online-Kommunikationsplattformen für Wissenschaft und Investoren

Digitale Kommunikationskennzahlen für 2023:

Plattform	Follower/Abonnenten	Engagement-Rate
LinkedIn	14,237	3.2%
Twitter	8,456	2.7%
Unternehmenswebsite	45.612 einzelne Besucher	4.1%

Oncolytics Biotech Inc. (ONCY) – Geschäftsmodell: Kundensegmente

Onkologische Forschungseinrichtungen

Oncolytics Biotech richtet sich an akademische und Forschungseinrichtungen, die sich auf Krebsstudien konzentrieren.

Institutionstyp	Mögliche Kooperationen	Anzahl potenzieller Ziele
Akademische Forschungszentren	Unterstützung bei klinischen Studien	87 große onkologische Forschungszentren
Krebsforschungsinstitute	Präklinische Studien	42 spezialisierte Krebsforschungseinrichtungen

Pharmaunternehmen

Potenzielle Pharmapartner für die Arzneimittelentwicklung und -vermarktung.

Unternehmensgröße	Mögliche Art der Zusammenarbeit	Zielmarkt
Große Pharmaunternehmen	Lizenzierung und Co-Entwicklung	12 erstklassige Entwickler von Onkologiemedikamenten
Mittelständische Biotech-Unternehmen	Forschungspartnerschaft	23 spezialisierte Onkologie-Biotech-Unternehmen

Krebsbehandlungszentren

Gesundheitseinrichtungen, die fortschrittliche Krebstherapien implementieren.

• 1.500 spezialisierte Krebsbehandlungszentren in Nordamerika
• Mögliche Standorte für klinische Studien
• Direkte Umsetzung innovativer Therapien

Teilnehmer an klinischen Studien

Patientenkategorie	Anzahl potenzieller Teilnehmer	Krebsarten
Patienten mit metastasiertem Krebs	8.700 potenzielle Teilnehmer	Brust-, Darm- und Lungenkrebs
Patienten mit refraktärem Krebs	3.200 potenzielle Teilnehmer	Krebserkrankungen im fortgeschrittenen Stadium

Potenzielle Patienten mit bestimmten Krebsarten

Gezielte Patientengruppen für spezielle Therapien.

• Brustkrebs: 3,8 Millionen potenzielle Patienten
• Darmkrebs: 1,4 Millionen potenzielle Patienten
• Lungenkrebs: 2,2 Millionen potenzielle Patienten

Oncolytics Biotech Inc. (ONCY) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2023 meldete Oncolytics Biotech Forschungs- und Entwicklungskosten in Höhe von 14,8 Millionen US-Dollar.

Jahr	F&E-Ausgaben	Prozentsatz der Gesamtausgaben
2023	14,8 Millionen US-Dollar	68.5%
2022	12,3 Millionen US-Dollar	65.2%

Kosten für das Management klinischer Studien

Die Ausgaben für klinische Studien für Oncolytics Biotech beliefen sich im Jahr 2023 auf insgesamt etwa 8,6 Millionen US-Dollar.

• Laufende Kosten der AWARE-1-Studie: 3,2 Millionen US-Dollar
• Studie zu metastasiertem Brustkrebs in Pelareorep: 2,5 Millionen US-Dollar
• Zusätzliche Unterstützung für klinische Forschung: 2,9 Millionen US-Dollar

Aufrechterhaltung des geistigen Eigentums

Jährliche Kosten für geistiges Eigentum und Patentpflege: 1,2 Millionen US-Dollar.

Gehälter für wissenschaftliches Personal

Personalkategorie	Jährliche Gehaltsspanne	Gesamte Personalkosten
Leitende Forschungswissenschaftler	$120,000 - $180,000	2,4 Millionen US-Dollar
Wissenschaftliche Mitarbeiter	$65,000 - $95,000	1,6 Millionen US-Dollar
Klinische Forschungsmanager	$100,000 - $150,000	1,8 Millionen US-Dollar

Labor- und Technologieinfrastruktur

Gesamtinvestition in Infrastruktur und Technologie im Jahr 2023: 5,4 Millionen US-Dollar.

• Wartung der Laborausrüstung: 2,1 Millionen US-Dollar
• Modernisierung der Technologieinfrastruktur: 1,8 Millionen US-Dollar
• Computergestützte Forschungssysteme: 1,5 Millionen US-Dollar

Oncolytics Biotech Inc. (ONCY) – Geschäftsmodell: Einnahmequellen

Mögliche zukünftige Arzneimittellizenzvereinbarungen

Im vierten Quartal 2023 verfügt Oncolytics Biotech über keine aktiven Lizenzvereinbarungen für Arzneimittel, die Einnahmen generieren. Das Hauptaugenmerk des Unternehmens liegt weiterhin auf der Entwicklung von REOLYSIN (Pelareorep), einer potenziellen Krebstherapie.

Forschungsstipendien und Finanzierung

Jahr	Finanzierungsquelle	Betrag
2023	National Institutes of Health (NIH)	1,2 Millionen US-Dollar
2023	Kanadische Krebsforschungsgesellschaft	$450,000

Strategische Pharmapartnerschaften

Aktuelle strategische Partnerschaften ab 2024:

• Zusammenarbeit mit Merck KGaA für klinische Studien zu REOLYSIN
• Forschungskooperation mit dem MD Anderson Cancer Center

Mögliche Kommerzialisierung der Therapie

Aktuelle Marktkapitalisierung von Oncolytics Biotech: 48,3 Millionen US-Dollar (Stand Februar 2024)

Therapie	Entwicklungsphase	Potenzieller Marktwert
REOLYSIN	Klinische Studien der Phasen 2/3	Geschätzter potenzieller Markt von 500 Millionen US-Dollar

Forschungskooperationsvereinbarungen

Aktuelle Fördermittel für Forschungskooperationen:

• MD Anderson Cancer Center der University of Texas: 2,1 Millionen US-Dollar
• Onkologisches Forschungsprogramm der Stanford University: 1,5 Millionen US-Dollar

Gesamte Forschungsförderung für 2023: 5,25 Millionen US-Dollar

Oncolytics Biotech Inc. (ONCY) - Canvas Business Model: Value Propositions

You're looking at the core value Oncology Biotech Inc. (ONCY) brings to the table with its lead candidate, pelareorep, as of late 2025. This isn't just about a drug; it's about fundamentally changing how certain hard-to-treat tumors respond to therapy.

Converting immunologically cold tumors to hot via immune activation

The main value lies in pelareorep's mechanism of action. It's an intravenously delivered oncolytic virus designed to activate the body's own immune system against cancer cells. This process promotes an inflamed tumor phenotype, effectively turning immunologically "cold" tumors "hot," making them responsive to immune-based treatments. Key Opinion Leader feedback has validated this ability, especially in cancers like KRAS-mutated colorectal cancer.

Strong survival signal in 1L mPDAC: 21.9% 2-year survival rate

The data in first-line metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) is compelling, showing a significant step up from historical norms. This is a major value driver, given how resistant this cancer is to current immunotherapy approaches.

Metric	Value	Context/Benchmark
2-Year Survival Rate (Pelareorep + Chemo)	21.9%	In 1L mPDAC patients (based on 100 patients in a post-hoc analysis).
Historical 2-Year Survival Benchmark	9.2%	For standard chemotherapy regimens in 1L mPDAC.
1-Year Survival Rate (Pelareorep + Chemo)	45%	In an ongoing, 55-patient pancreatic cancer cohort of the GOBLET trial (in 13 evaluable subjects).

Platform immunotherapy with demonstrated synergy across multiple approved oncology treatments

Pelareorep is positioned as a platform therapy, meaning its value is amplified when used with existing, approved treatments. This synergy is key for broad applicability and potential combination strategies.

• Data shows synergy with checkpoint inhibitors, achieving an objective response rate of 62% when combined with chemotherapy and a CPI.
• In HR+/HER2- metastatic breast cancer (BRACELET-1), the pelareorep + paclitaxel arm showed a median Progression-Free Survival (PFS) benefit of 5.7 months over chemotherapy alone.
• In colorectal cancer (REO 022 trial), the pelareorep + paclitaxel combination demonstrated a median PFS of 16.6 months versus 6.4 months for paclitaxel alone.
• It has been evaluated in combination with modified FOLFIRINOX in metastatic pancreatic cancer.

Favorable safety profile across over 1,100 treated patients

A de-risked safety profile is a significant value proposition for regulators and potential partners. The drug is administered intravenously and has a manageable side-effect profile, which is a positive characteristic when combining with intensive regimens.

The updated safety analysis covers over 1,200 patients dosed to date. Over 300 of these patients had various gastrointestinal tumors. The most frequent adverse events were Grade 1 and 2, specifically flu-like symptoms such as fever, chills, fatigue, nausea, vomiting, and diarrhea. Importantly, Grade 3 or 4 adverse events associated with chemotherapy do not appear to be modified by adding pelareorep.

Potential for accelerated regulatory approval pathways

Oncology Biotech Inc. (ONCY) has existing designations that streamline the path to market for its key indications. This reduces the time and capital required to reach commercialization.

• FDA Fast Track designation received in 2017 for metastatic breast cancer.
• FDA Fast Track designation received in 2022 for pancreatic cancer.
• The company is in active discussions with the FDA to finalize parameters for a registration-directed pivotal study in 1L mPDAC, with potential initiation of trial activities by Q4 2025.
• The proposed registration study design includes a planned interim efficacy analysis to enable early assessment of potential clinical benefit, which could support an accelerated registration timeline if successful.

Oncolytics Biotech Inc. (ONCY) - Canvas Business Model: Customer Relationships

You're looking at how Oncolytics Biotech Inc. (ONCY) manages its critical external relationships as it pushes its lead asset, pelareorep, toward potential registration. For a clinical-stage biotech, these aren't just 'customers' in the traditional sense; they are the regulators, the scientific community, the financial backers, and the patient advocates who collectively determine the company's success and valuation.

Direct, high-touch engagement with Key Opinion Leaders (KOLs) and oncologists

Oncolytics Biotech Inc. maintains direct engagement with Key Opinion Leaders (KOLs) to ensure clinical trial designs are relevant and to validate the science behind pelareorep. The company held a recent Key Opinion Leader event which reinforced the clinical promise of pelareorep in metastatic pancreatic ductal adenocarcinoma (mPDAC) and other gastrointestinal (GI) cancers. If efficacy signals in indications like relapsed anal carcinoma persist in Stage 2 expansion cohorts, the company will engage with its scientific advisory board and KOLs to optimize development in that indication. This high-touch approach is standard for translating strong clinical data into accepted standards of care.

• Deloitte reports that more than 80% of pharma executives rely on external experts to shape clinical and commercial strategy in 2025.
• KOL involvement signals to regulatory authorities and Institutional Review Boards that research is clinically relevant and ethically sound.

Intensive regulatory dialogue with the U.S. FDA and other agencies

Regulatory alignment is a primary focus for Oncolytics Biotech Inc., especially for its Fast Track-designated programs in metastatic breast cancer and pancreatic cancer. The company confirmed active discussions with the U.S. Food and Drug Administration (FDA) to finalize parameters for a registration-enabled pivotal study in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), with study start-up activities potentially commencing before the end of 2025. Specifically, the company was scheduled to meet with the FDA in mid-November 2025 to advance these study details. For the breast cancer program, a prior Type C meeting in June 2024 supported the planned potential registration-enabling trial, with the FDA supporting progression-free survival as the primary endpoint. Furthermore, Germany's Paul-Ehrlich-Institute (PEI) gave the go-ahead to fully enroll the GOBLET Cohort 5 study in pancreatic cancer following a positive safety review.

The planned pivotal trial for mPDAC is designed with three arms to establish regulatory rigor:

Arm Number	Treatment Regimen	Primary Endpoint Focus
1 (Control)	Gemcitabine + nab-paclitaxel (GnP)	Overall Survival (OS)
2 (Investigational)	GnP + pelareorep	Overall Survival (OS)
3 (Investigational)	GnP + pelareorep + checkpoint inhibitor (CPI)	Overall Survival (OS)

This design includes a planned interim efficacy analysis to enable early assessment of clinical benefit.

Investor relations focused on non-dilutive funding and shareholder value

Investor relations efforts are heavily concentrated on securing capital that minimizes shareholder dilution while funding key clinical milestones. Oncolytics Biotech Inc. has actively managed its financing structure through late 2025. The company reported cash and cash equivalents of $12.4 million as of September 30, 2025, which management indicated provides runway into the first quarter of 2026 without requiring additional funding. However, the Q3 2025 net loss was reported at $14.4 million, an increase from $9.5 million in the same period last year, underscoring the need for capital access. The company is a development-stage entity with no current revenue generation and an Earnings Per Share (EPS) of negative $0.27 trailing twelve months.

Here's a quick look at the capital structure and recent funding activities:

Financing Instrument/Metric	Amount/Value	Date/Period End
Cash & Cash Equivalents	$12.4 million	September 30, 2025
Q3 2025 Net Loss	$14.4 million	Three months ended September 30, 2025
Share Purchase Agreement (SPA) Maximum	Up to US$20 million	April 10, 2025 (over 15 months)
At-The-Market (ATM) Financing Maximum	Up to $50 million	Filed as of October 17, 2025
Total Institutional Investors	3	As of late 2025

The ATM financing with BTIG, LLC, offers a flexible means to secure capital at current market prices. The company's current market capitalization is approximately $109.33 million, with shares trading at $1.03 as of November 19, 2025.

Collaboration management with academic and advocacy groups (PanCAN)

Managing strategic collaborations is vital for advancing clinical proof points, particularly in complex indications like pancreatic cancer. Oncolytics Biotech Inc. has a key relationship with The Pancreatic Cancer Action Network (PanCAN). This relationship is formalized through a significant financial contribution supporting ongoing research. The GOBLET Cohort 5 study, which is evaluating pelareorep in newly diagnosed metastatic pancreatic cancer patients combined with modified FOLFIRINOX with or without atezolizumab, is directly supported by this partnership.

• GOBLET Cohort 5 for pancreatic cancer is funded by a $5 million grant from PanCAN.
• The company also has a collaboration with the Global Coalition for Adaptive Research (GCAR) to support pancreatic cancer research.
• Pelareorep has received Fast Track designation from the FDA for both metastatic breast and pancreatic cancers.

Finance: draft 13-week cash view by Friday.

Oncolytics Biotech Inc. (ONCY) - Canvas Business Model: Channels

The channels for Oncolytics Biotech Inc. (ONCY) are centered on clinical validation, regulatory engagement, and capital market communication to advance pelareorep.

Global network of clinical trial sites and academic research centers

The GOBLET study is currently being conducted at 17 centers in Germany for its Phase 1/2 indications. Oncolytics Biotech Inc. submitted a protocol amendment in September 2025 to open U.S. clinical sites for the GOBLET trial, with Northwestern University expected to serve as one of these locations. Enrollment for Cohort 4 in relapsed, unresectable SCAC indication is at 20 evaluable patients as of September 2025, with completion expected by the end of 2025.

Scientific conferences (ASCO GI, etc.) for data dissemination

Data dissemination channels include major medical meetings. Oncolytics Biotech Inc. presented data featuring pelareorep at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco from January 23-25, 2025. Further data from the GOBLET clinical trial was presented in a poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2025.

Direct communication with regulatory bodies (FDA, PEI)

Direct engagement with regulatory agencies is a critical channel for trial progression. Germany's Paul-Ehrlich-Institute (PEI) provided clearance for Oncolytics Biotech Inc. to continue enrolling patients in its pancreatic cancer trial (GOBLET Cohort 5) following a safety review. The company initiated regulatory discussions with the U.S. Food and Drug Administration (FDA) for a potential registration-enabled pivotal study in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) in July 2025, expecting to commence study start-up activities before the end of 2025. By November 2025, Oncolytics Biotech Inc. announced alignment with the FDA on the pivotal study design.

Future licensing agreements with large pharmaceutical partners

The strategy involves advancing pelareorep through late-stage clinical testing to present the highest chance of success and greatest commercial opportunity, positioning the company for potential collaborations with industry leaders. The company is actively seeking strategic collaborations as part of its financing strategy.

Investor roadshows and SEC/SEDAR filings for capital markets

Investor communication channels include direct presentations and mandatory regulatory filings. CEO Jared Kelly presented at the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 9 and 10, 2025. The company filed a Form 6-K on October 10, 2025, submitting its corporate presentation to the SEC. For capital raising, Oncolytics Biotech Inc. launched an at-the-market offering of up to $50,000,000 in common shares, with the agent receiving a 3.0% commission. As of June 30, 2025, common shares outstanding were 97,407,903. The cash and cash equivalents balance as of September 30, 2025, was $12.4 million. The net loss for the period ending September 30, 2025, was $27.3 million.

Key Channel Metrics for Oncolytics Biotech Inc. as of Late 2025:

Channel Metric	Value/Amount	Date/Period Reference
GOBLET Trial Centers (Germany)	17	Q1-Q3 2025
U.S. Clinical Sites Planned	1+ (Including Northwestern University)	September 2025
SCAC Cohort 4 Enrollment (Target)	20 evaluable patients	Expected completion by end of 2025
At-The-Market Offering Size	Up to $50,000,000	October 2025 Filing
Agent Commission on Offering	3.0%	October 2025 Filing
Common Shares Outstanding	97,407,903	June 30, 2025
Cash and Cash Equivalents	$12.4 million	September 30, 2025
Net Loss Reported	$27.3 million	Period ending September 30, 2025

Oncolytics Biotech Inc. (ONCY) - Canvas Business Model: Customer Segments

You're looking at the key groups Oncolytics Biotech Inc. (ONCY) targets for its pelareorep asset, which is a crucial part of understanding their path to commercialization and future valuation. Here are the concrete segments and the numbers we see as of late 2025.

Patients with hard-to-treat solid tumors, primarily mPDAC and mBC

This group represents the end-users who stand to benefit from pelareorep, which is designed to turn immunologically "cold" tumors "hot".

• The company is pursuing a potential registration-enabling trial in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
• In the BRACELET-1 study for metastatic breast cancer, the pelareorep + paclitaxel arm showed a 5.7-month PFS benefit over chemotherapy alone.
• In the IND-213 metastatic breast cancer study, median overall survival in the pela group was nearly double that in the control arm.
• For relapsed anal carcinoma (GOBLET Cohort 4), an interim objective response rate of 33% was reported, including one complete response lasting more than 15 months.
• GOBLET Cohort 5, targeting newly diagnosed metastatic pancreatic cancer, is set for Stage 1 enrollment with 30 patients across two treatment arms.
• The overall global oncology market was estimated at US$345.1 billion in 2025.

Large pharmaceutical and biotech companies seeking oncology assets

These are potential acquirers or partners, attracted by the clinical data and the clear regulatory path Oncolytics Biotech Inc. is establishing. The team's pedigree is relevant here; the CEO and CBO were involved in Ambrx Biopharma's US$2 billion acquisition by Johnson & Johnson.

Oncolytics Biotech Inc. has secured flexible financing options, signaling a need to bridge to key milestones before a potential partnership or acquisition. They have:

• An at-the-market (ATM) equity financing agreement with BTIG, LLC to sell up to $50 million in common stock.
• A Share Purchase Agreement (SPA) with Alumni Capital LP to sell up to US$20 million worth of stock over a 15-month period.
• Management acknowledges the need for additional financing to sustain operations beyond March 2026.

Institutional investors and specialist biotech funds (e.g., Alumni Capital)

This segment is focused on the capital structure and ownership base. As of the latest filings, the institutional picture looks like this:

Metric	Value as of Late 2025
Total Institutional Owners (13F/G Filers)	59
Total Institutional Shares Held (Long)	2,887,189
Institutional Ownership Percentage	6.82%
Share Price (as of Dec 2, 2025)	$0.88 / share
Market Capitalization (Approx.)	$119.47 million
Total Shares Outstanding (Millions)	106

Key named investors include Alumni Capital, which entered via an SPA on April 10, 2025. Other major holders as of September 30, 2025, show significant positions:

• Morgan Stanley: 383,346 shares
• Citadel Advisors Llc: 382,051 shares
• Marshall Wace, Llp: 323,982 shares

Honestly, the low institutional ownership percentage of 6.82% suggests significant room for institutional accumulation as clinical milestones are hit.

Academic and cooperative oncology groups (e.g., GCAR)

These groups provide critical validation, trial infrastructure, and often, non-dilutive funding, which is key for a clinical-stage company. Oncolytics Biotech Inc. has formalized relationships here:

• The company established a collaboration with the Global Coalition for Adaptive Research (GCAR) for the pancreatic cancer program.
• The GOBLET Cohort 5 study is supported by a $5 million grant from the Pancreatic Cancer Action Network (PanCAN).
• Oncolytics established a Gastrointestinal Tumor Scientific Advisory Board on November 4, 2025.

Finance: draft 13-week cash view by Friday.

Oncolytics Biotech Inc. (ONCY) - Canvas Business Model: Cost Structure

You're looking at the core expenditures for Oncolytics Biotech Inc. (ONCY) as they push pelareorep through late-stage clinical development. For a clinical-stage biopharma, the cost structure is almost entirely driven by R&D, which is where the bulk of the cash burn happens. Honestly, this is the engine room of the business model right now.

The primary cost drivers are Research and Development (R&D) expenses, which cover everything from running the trials to the actual production of the drug substance. General and Administrative (G&A) costs are the next big bucket, covering the corporate overhead needed to keep the lights on and the SEC filings current.

Here's the quick math on the first quarter of 2025 expenditures, based on their reported figures:

• Research and Development (R&D) expenses, including clinical trial costs: totaled $4.1 million.
• General and Administrative (G&A) expenses, including personnel and legal fees: totaled $3.0 million.

To give you a clearer picture of where that R&D dollar went in Q1 2025, we can look at the components, which are reported in thousands of Canadian dollars (CAD). This level of detail helps map the spend against clinical milestones.

R&D Component (Q1 2025)	Amount (in thousands of CAD)	Change from Q1 2024 (in thousands of CAD)
Clinical trial expenses	$516	($286)
Manufacturing and related process development expenses	$578	($2,600)
Intellectual property expenses	$149	$23

Notice the significant drop in manufacturing and related process development costs year-over-year for Q1 2025, down by $2,600 thousand CAD, which suggests a shift in the manufacturing schedule or a transition to a different phase of production for pelareorep. Still, manufacturing costs for the pelareorep drug substance and product remain a key component of the overall R&D spend.

General and Administrative (G&A) expenses are the second major category. These costs are primarily public company-related expenses, office costs, share-based compensation, and legal/accounting fees. For Q1 2025, the G&A spend was $3.0 million. This figure was noted as consistent with the prior year, which is a good sign of cost control in overhead, even as the company progresses its pipeline.

Looking at the subsequent quarter, Q2 2025, the cost structure showed some movement, which is important for your near-term cash view. R&D expenses decreased to $2.8 million CAD, primarily due to lower clinical trial expenses as the focus narrowed to Cohort 5 of the GOBLET study, which is supported by the Pancreatic Cancer Action Network award. G&A expenses for Q2 2025 were $2.9 million CAD, down from $3.4 million CAD in Q2 2024, mainly due to lower public company-related expenses, though personnel costs partially offset this reduction.

The total cash used in operating activities for the first six months of 2025 was $12.0 million CAD. This reflects the ongoing investment required to support the clinical programs for pelareorep.

Here is a summary of the key expense figures we have for the first half of 2025, using the most recent data points available:

• Q1 2025 R&D Expenses: $4.1 million (Source 1)
• Q1 2025 G&A Expenses: $3.0 million (Source 1)
• Q2 2025 R&D Expenses: $2.8 million CAD (Source 6)
• Q2 2025 G&A Expenses: $2.9 million CAD (Source 6)
• Net Cash Used in Operating Activities (6 months ended June 30, 2025): $12.0 million CAD (Source 6)

Finance: draft 13-week cash view by Friday.

Oncolytics Biotech Inc. (ONCY) - Canvas Business Model: Revenue Streams

You're looking at the current financial reality for Oncolytics Biotech Inc. (ONCY) as of late 2025. Honestly, for a clinical-stage company like this, the revenue stream block in the Business Model Canvas is almost entirely populated by non-operating capital sources right now, which is typical for the sector.

Currently pre-commercial with $0.00 actual revenue reported in Q3 2025

Oncolytics Biotech Inc. (ONCY) is operating in a pre-commercial phase, meaning product sales are not yet a source of income. The financial results for the third quarter ended September 30, 2025, reflect this, showing a net loss of $14.4 million for the quarter. Furthermore, the company reported an Earnings Per Share (EPS) of -$0.10 for Q3 2025. The trailing twelve months ending September 30, 2025, showed earnings of -$25.2 million. This lack of operating revenue is supported by statements indicating no current revenue generation.

Non-dilutive funding from grants

A key non-dilutive inflow has been grant funding, specifically the award from the Pancreatic Cancer Action Network (PanCAN). Oncolytics Biotech Inc. was selected to receive a $5 million Therapeutic Accelerator Award from PanCAN. This $5 million grant is earmarked to support the next stage of research, including a Phase 2 study arm evaluating pelareorep in combination with modified FOLFIRINOX chemotherapy.

Equity financing through ATM and Share Purchase Agreements

To bridge the gap until potential commercialization, Oncolytics Biotech Inc. has secured access to capital through equity financing mechanisms. Most recently, as of October 2025, Oncolytics Biotech Inc. entered into a new at-the-market (ATM) equity financing agreement allowing the company to sell up to $50 million in common stock. This deal, managed by BTIG, LLC, provides a flexible means to secure capital for operations and research efforts by selling shares directly on the market at prevailing prices. This is a significant facility, similar to a previous $50 million USD ATM offering launched in August 2024.

Here's a quick look at the capital sources supporting operations as of late 2025:

Revenue/Funding Stream Type	Specific Source/Program	Reported Amount/Status (Late 2025)
Actual Operating Revenue	Product Sales	$0.00 (Pre-commercial)
Non-Dilutive Funding (Grant)	PanCAN Therapeutic Accelerator Award	$5 million
Equity Financing (ATM Facility)	Agreement with BTIG, LLC (as of Oct 2025)	Up to $50 million available
Operating Performance (Loss)	Q3 2025 Net Loss	$14.4 million

Future potential revenue from upfront payments and milestones from licensing deals

The primary long-term revenue potential for Oncolytics Biotech Inc. lies in successful commercialization, which is often preceded by strategic partnerships. The company is actively advancing discussions to secure these deals. Future revenue streams are structured to include:

• Upfront payments received upon signing a licensing or collaboration agreement.
• Milestone payments triggered by achieving specific clinical or regulatory success points.

Future product sales royalties or direct sales post-approval

Once a therapeutic candidate, like pelareorep, achieves regulatory approval in key markets, the revenue model shifts to commercial realization. This is the ultimate goal for the company's value creation. This future stream is anticipated to come from:

• Royalty payments based on net sales generated by a commercial partner.
• Direct sales revenue if Oncolytics Biotech Inc. chooses to retain or build out its own commercial infrastructure in certain territories post-approval.

Finance: draft 13-week cash view by Friday.